Understanding the pathophysiological changes via untargeted metabolomics in COVID‐19 patients

Coronavirus disease 2019 (COVID‐19) is an infectious respiratory disease caused by a new strain of the coronavirus. There is limited data on the pathogenesis and the cellular responses of COVID‐19. In this study, we aimed to determine the variation of metabolites between healthy control and COVID‐19 via the untargeted metabolomics method. Serum samples were obtained from 44 COVID‐19 patients and 41 healthy controls. Untargeted metabolomics analyses were performed by the LC/Q‐TOF/MS (liquid chromatography quadrupole time‐of‐flight mass spectrometry) method. Data acquisition, classification, and identification were achieved by the METLIN database and XCMS. Significant differences were determined between patients and healthy controls in terms of purine, glutamine, leukotriene D4 (LTD4), and glutathione metabolisms. Downregulations were determined in R‐S lactoglutathione and glutamine. Upregulations were detected in hypoxanthine, inosine, and LTD4. Identified metabolites indicate roles for purine, glutamine, LTD4, and glutathione metabolisms in the pathogenesis of the COVID‐19. The use of selective leukotriene D4 receptor antagonists, targeting purinergic signaling as a therapeutic approach and glutamine supplementation may decrease the severity and mortality of COVID‐19. Highlights COVID‐19 was seen in 216 countries worldwide and is now accepted as a pandemic. There is no specific and proven vaccine or antiviral therapy. Understanding COVID‐19 mechanism is so vital importance. Changed purine, glutamine, glutathione and LTD4 metabolism were detected in COVID‐19 patients. The use of selective leukotriene D4 receptor antagonists, targeting purinergic signaling as a therapeutic approach and glutamine supplementation may decrease the severity and mortality of COVID‐19.